IFNA2 and infection: During acute or early infection stages, initial clinical trials have shown that parenteral administration of IFN-α2b can effectively inhibit viral replication before the establishment of viral reservoirs, leading to temporary reductions in viral load and a delayed viral rebound after treatment cessation.